Incannex Enlists Investigators for Phase 2/3 Study of IHL-42X for Sleep Apnea

Incannex Healthcare Ltd, a clinical-stage pharmaceutical company developing medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies, has recruited two lead principal investigators for the Investigational New Drug opening phase 2/3 clinical trial investigating IHL-42X, a cannabinoid combination product, for the treatment of obstructive sleep apnea (OSA).  John D. Hudson, MD, principal investigator for FutureSearch Trials…

Read More